NBC Securities Inc. Acquires 955 Shares of Novo Nordisk A/S (NYSE:NVO)

NBC Securities Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVOFree Report) by 12.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,475 shares of the company’s stock after purchasing an additional 955 shares during the quarter. NBC Securities Inc.’s holdings in Novo Nordisk A/S were worth $1,188,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Morgan Stanley boosted its position in shares of Novo Nordisk A/S by 96.5% during the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after acquiring an additional 4,526,199 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Novo Nordisk A/S by 109.2% during the 3rd quarter. Royal Bank of Canada now owns 3,643,061 shares of the company’s stock valued at $331,300,000 after acquiring an additional 1,901,429 shares during the last quarter. Northern Trust Corp boosted its position in shares of Novo Nordisk A/S by 110.4% during the 3rd quarter. Northern Trust Corp now owns 3,585,407 shares of the company’s stock valued at $326,057,000 after acquiring an additional 1,881,264 shares during the last quarter. Soros Fund Management LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $138,759,000. Finally, Natixis Advisors L.P. boosted its position in shares of Novo Nordisk A/S by 96.2% during the 3rd quarter. Natixis Advisors L.P. now owns 2,997,073 shares of the company’s stock valued at $272,554,000 after acquiring an additional 1,469,489 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Monday. BMO Capital Markets started coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Argus increased their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. Finally, The Goldman Sachs Group started coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target on the stock. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $145.67.

Read Our Latest Research Report on Novo Nordisk A/S

Novo Nordisk A/S Trading Up 0.3 %

NVO stock traded up $0.43 during midday trading on Wednesday, reaching $140.80. The company’s stock had a trading volume of 2,640,226 shares, compared to its average volume of 3,369,956. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The stock has a fifty day simple moving average of $131.97 and a two-hundred day simple moving average of $121.17. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $144.50. The firm has a market capitalization of $631.84 billion, a price-to-earnings ratio of 48.55, a PEG ratio of 1.39 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The business had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. On average, equities research analysts predict that Novo Nordisk A/S will post 3.41 EPS for the current year.

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.